



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Virology

ESPS manuscript NO: 13790

Title: Ledipasvir and Sofosbuvir: Interferon free therapy for HCV genotype 1 patients.

Reviewer code: 00000794

Science editor: Fang-Fang Ji

Date sent for review: 2014-09-02 18:51

Date reviewed: 2014-11-06 06:36

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D: Fair		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The Authors should try to present the data more clearly, for example using a table. The text has to be revised by an English speaking person since many sentences are not understandable



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Virology

ESPS manuscript NO: 13790

Title: Ledipasvir and Sofosbuvir: Interferon free therapy for HCV genotype 1 patients.

Reviewer code: 02943094

Science editor: Fang-Fang Ji

Date sent for review: 2014-09-02 18:51

Date reviewed: 2014-10-01 00:25

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair		BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This review the highlights of recently published studies of Sofosbuvir-Ledipasvir for HCV genotype 1. The article gives the idea that, aside from cost, this combination is the solution for HCV genotype 1. The sentence "The Ledipasvir and Sofosbuvir therapy produces very good results in different subgroups of patients regardless of patient's race, ALT levels, sex and host genetic factors." is overly optimistic. There are ongoing issues that are not addressed. Specifically, the author does not address patients excluded from these studies. Although some with cirrhosis are allowed in these studies, none had advanced cirrhosis. Most had platelet counts over 90. What about sicker cirrhotics - should we expect the same level of SVR? What about those with decompensated cirrhosis? HIV co-infection? Given the cost of medication, comment on whether this is a realistic approach to HCV treatment in most parts of the world.